Printer Friendly

Sanofi-aventis Japan Acquires Production and Sales Rights of Ancaron Antiarrhythmic Agent from Taisho Pharmaceutical.

Tokyo, Japan, Oct 15, 2005 - (JCNN) - Sanofi-aventis Japan announced on October 11 that it has acquired the rights to produce and sell Ancaron (amiodarone hydrochloride), an antiarrhythmic agent, from Taisho Pharmaceutical.

In the meantime, Taisho Pharmaceutical and its subsidiary Taisho Toyama Pharmaceutical will continue to manufacture and sell the agent by signing a consignment contract with Sanofi-aventis Japan.

Ancaron, which was first introduced to Japan in 1992, is currently marketed over 100 countries worldwide.

Source: JCN

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Oct 15, 2005
Previous Article:Alfresa Pharma to Become Distributor of Anafranil Antidepressant.
Next Article:AnGes MG, Osaka University, Aoki Undertake Co-development of Fully Bioabsorbable Stent.

Related Articles
Aventis Pharma Obtains Additional Approval for Taxoid Antitumor Agent TAXOTERE Injection.
Drug giant picks NJ for 670,000 s/f HQ.
Astellas Pharma, Sanofi-aventis Japan to Co-promtoe Myslee Tablet, Hypnotic Drug.
Astellas Pharma, Taisho Pharmaceutical Both Deny Acquisition of Zepharma by Taisho Pharmaceutical.
REIT buys 300,000 s/f NJ complex.
Astellas and Toyama Chemical Announce Basic Licensing Agreement on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811.
Taiho Pharmaceutical, Sanofi-aventis Conclude Licensing Agreement for Oral Pyrimidine Fluoride-derived Anticancer Agent TS-1.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |